Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lactitol

FDA-approved product (for solution, oral), marketed as Pizensy.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Lactitol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Constipation
  • Constipation disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Osmotically acting laxatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Lactitol, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis28.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lactitol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lactitol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition

    NCT00951847 · start 2006-10

    Registered record
    Registry ID
    NCT00951847
    Conditions
    Healthy
    Interventions
    oxcarbazepine 300 mg/5 mL oral suspension
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-10
    Completion
    2006-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionoxcarbazepine 300 mg/5 mL oral suspension
    PhaseNot applicable
    Registry statusCompleted

  • fMRI and Ghlrein in Obesity and Binge Eating Disorder

    NCT02038712 · start 2006-06

    Registered record
    Registry ID
    NCT02038712
    Conditions
    Obesity; Binge Eating Disorder
    Interventions
    Fed Condition; Fasted condition; Blood samples; Subjective appetite ratings; fMRI scan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-06
    Completion
    2013-09
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Binge Eating Disorder
    InterventionFed Condition; Fasted condition; Blood samples; Subjective appetite ratings +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions

    NCT01155908 · start 2005-04

    Registered record
    Registry ID
    NCT01155908
    Conditions
    Healthy
    Interventions
    Amlodipine Besylate / Benazepril Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-05
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAmlodipine Besylate / Benazepril Hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions

    NCT00829673 · start 2004-06

    Registered record
    Registry ID
    NCT00829673
    Conditions
    Healthy
    Interventions
    Dexmethylphenidate Hydrochloride; Dexmethylphenidate Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-06
    Completion
    2004-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDexmethylphenidate Hydrochloride; Dexmethylphenidate Hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg

    NCT00649116 · start 2002-12

    Registered record
    Registry ID
    NCT00649116
    Conditions
    Healthy
    Interventions
    Metoprolol Tartrate Tablets 100 mg; Lopressor® Tablets 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMetoprolol Tartrate Tablets 100 mg; Lopressor® Tablets 100 mg
    PhasePhase 1
    Registry statusCompleted